The present invention relates to compounds of Formula (I):
1
wherein A
1
is methylene, ethylene or propylene group and A
2
is N or CR
5
, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
Peptide inhibitors of hepatitis C virus NS3 protein
申请人:——
公开号:US20020177725A1
公开(公告)日:2002-11-28
This invention relates to a novel class of peptides having the Formula (I):
1
Which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.
Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
申请人:——
公开号:US20020123468A1
公开(公告)日:2002-09-05
The present invention relates to ketoamide and ketoester compounds of Formula (I):
1
wherein W is —NH— or —O—, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
Processes and host cells for genome, pathway, and biomolecular engineering
申请人:enEvolv, Inc.
公开号:US10370654B2
公开(公告)日:2019-08-06
The present disclosure provides compositions and methods for genomic engineering.
本公开提供了基因组工程的组合物和方法。
Peptide inhibitors of hepatitis C virus NS3 protease
申请人:——
公开号:US20040147483A1
公开(公告)日:2004-07-29
This invention relates to a novel class of peptides having the Formula (I):
1
which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus (HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.